Clinical performance progress of BREAST participants: the impact of test-set participation

This study investigated the clinical audit history for a cohort of 39 participants in the BreastScreen Reader Assessment Strategy who have read for BreastScreen New South Wales in the period between 2010 and 2018, inclusively. Based on the year in which each radiologist completed his or her first test set, data of multiple clinical audit metrics from two calendar years before test-set reading were compared against similar data from three different periods after test-set completion. The same process was repeated after dividing radiologists into two subgroups based on their median screen-reading volume (3,688), to test if experience is a determinant of post-test set performance.RESULTS: On average, radiologists showed significant improvements (p
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

This study suggested that active surveillance could be a reasonable option for certain category of patients. This attitude is not without risks. A patient with DCIS on core needle biopsy could hide an invasive cancer in 25% of cases (12). Today, there are four randomized control trials of active surveillance offered to patients with low-grade DCIS: LORD (LOw Risk DCIS), COMET (Comparison of Operative to Monitoring and Endocrine Therapy), LORIS (LOw RISk DCIS) and LORETTA (10,13-16). Non-surgical approaches are of two types: active surveillance alone or associated with hormone therapy. There are some differences between the...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
AbstractPurpose of ReviewDuctal carcinoma in situ (DCIS) of the breast is a heterogenous intraductal disease that exists within a spectrum of intraepithelial abnormalities ranging from atypia to invasive carcinoma. The vast majority of DCIS is diagnosed in asymptomatic women on screening mammography as suspicious calcifications, but can less commonly present as a palpable mass, suspicious nipple discharge, or as suspicious enhancement in high-risk women being screened with MRI. The distinction between atypia and low-grade DCIS is nuanced, and significant overlap in the imaging appearance of DCIS coupled with interobserver ...
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research
CONCLUSION: For detecting underestimated DCIS, CESM was superior to mammography and breast US, and comparable to breast MRI.PMID:34776365 | DOI:10.1016/j.clbc.2021.10.004
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
Women undergoing breast MRI for evaluation of ductal carcinoma in situ experienc...Read more on AuntMinnie.comRelated Reading: Contrast-enhanced mammography can predict underestimated DCIS Prediction models can reduce false positives in breast MRI screening DCIS shows as nonmass enhancement on breast MRI Health practitioners overestimate likelihood of disease, study says Women with DCIS have 3x the risk of breast cancer death
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
CONCLUSIONS: There is low-/very low-certainty evidence to support the hypothesis that breast density change following endocrine therapy is a prognostic biomarker for treatment or prevention. Studies suggested a potentially large effect size with tamoxifen, but the evidence was limited. There was less evidence that breast density change following tamoxifen preventive therapy is a predictive biomarker than prognostic biomarker. Evidence for breast density change as a prognostic treatment biomarker was stronger for tamoxifen than aromatase inhibitors. There were no studies reporting mammographic density change following endoc...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: news
CONCLUSION: In DCIS patients, the rate of second breast cancers was 7.5%. Breast conservation, involved margins after lumpectomy and shortened hormonal therapy were associated with second cancers. Patients with involved margins after lumpectomy have the highest cancer detection rate and minimal unnecessary biopsies and follow-ups. Hence, ipsilateral breast ultrasound surveillance could be personalized for this high-risk group with mammographically dense breasts.PMID:34544658 | DOI:10.1016/j.clbc.2021.08.006
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
The three risk assessment tools now in use fall far short. Using the latest deep learning techniques, investigators are developing more personalized ways to locate women at high risk.John Halamka, M.D., president, Mayo Clinic Platform, and Paul Cerrato, senior research analyst and communications specialist, Mayo Clinic Platform, wrote this article.The promise of personalized medicine will eventually allow clinicians to offer individual patients more precise advice on prevention, early detection and treatment. Of course, the operative word iseventually.A closer examination of the screening tools available to detect breast c...
Source: Life as a Healthcare CIO - Category: Information Technology Source Type: blogs
The incidence of ductal carcinoma in situ (DCIS) is increasing due to more widespread mammographic screening. DCIS, the earliest form of breast cancer, is non-invasive at the time of detection. If DCIS tissues...
Source: BMC Research Notes - Category: Research Authors: Tags: Data note Source Type: research
CONCLUSION: RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.PMID:34406870 | DOI:10.1200/JCO.21.01083
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Mammography | Radiology | Study | Wales Health